Navigation Links
How a cancer drug leads to diabetes
Date:4/3/2012

The drug known as rapamycin is widely used by cancer and transplant patients, and there are hints that it might even help us put off old age and live longer. But, it also comes with a downside: rapamycin leads to diabetes in as many as 15 percent of the people who take it.

Now, researchers reporting in the April Cell Metabolism, a Cell Press publication, have figured out why that is. The drug turns the insulin signal off in muscle, to prevent muscle cells from taking blood sugar in.

"This is a drug that is pretty well known for its benefits," said Pere Puigserver of Dana-Farber Cancer Institute. "Rapamycin is one of the few drugs, maybe the only one, that extends lifespan in organisms from yeast to mice to primates."

But the drug's diabetic side effects are troubling, and Puigserver's team now finds they arise in an interesting way. The key is a single transcription factor in muscle known as YY1. Mice lacking YY1 are protected from diabetes when they take rapamycin.

That's because rapamycin changes YY1 within muscle and that shift leads to chemical and structural modifications of the genes encoding insulin signals. Those changes effectively turn insulin off, keeping sugar from coming in.

That rapamycin leads to long life even as it causes insulin resistance remains something of a paradox, Puigserver says. His team does have hints that there may be other factors at play. For instance, he says diet might make the difference between those who develop diabetes while on rapamycin and those who do not.

The results also have fundamental interest as perhaps the first instance in which the nutrient signal mTOR -- the target of rapamycin -- has been tied to epigenetic changes in the genome. (Epigenetic changes are defined as chemical modifications to DNA that can take place without any change in the underlying sequence of As, Gs, Ts and Cs.) The finding may reveal a more general mechanism by which other nutrient changes could act via mTOR to control the epigenetic state of genes, with impacts in metabolism and diseases.

On the practical side, the findings support the notion that at least some people taking rapamycin should also take anti-diabetic drugs, Puigserver says. These side effects will also need to be factored into any cost-benefit analysis of further uses of the drug, the researchers say, including for any future use in lifespan extension.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: